Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis Watch Now

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England

Glaxosmithkline Share News (GSK)

Stock Market news at - RSS News Feeds

Share News for Glaxosmithkline (GSK)

Share Price: 1,555.00Bid: 1,500.00Ask: 1,560.00Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 60.00Spread as %: 4.00%Open: 1,544.00High: 0.00Low: 0.00Yesterday’s Close: 1,555.00

UPDATE 2-Merck KGaA, Oncothyreon hit as cancer vaccine fails

Wed, 19th Dec 2012 12:32

By Maria Sheahan and Ben Hirschler

FRANKFURT, Dec 19 (Reuters) - An e
xperimental lung cancer vaccine from Germany's Merck KGaA failed to improve survival in a pivotal study, dealing a blow to the company and the high-risk field of using vaccines to fight tumours.

Stimuvax, which Merck licensed from U.S. biotech firm Oncothyreon, failed to increase overall survival in the Phase III clinical trial, the German chemicals and pharmaceuticals group said on Wednesday.

The trial's coordinating investigator, Frances Shepherd of the University of Toronto, said the result was disappointing, although she said 'notable treatment effects were observed in certain subgroups of patients'.

While this could mean that Merck might conduct more studies to try and find particular groups of patients who would benefit from the treatment, industry analysts were sceptical that Stimuvax had any future.

'Despite potential positive effects in subgroups, we consider the drug dead,' said Deutsche Bank analyst Holger Blum.

The trial was testing Stimuvax on more than 1,500 patients with stage III non-small cell lung cancer whose tumours could not be completely removed via surgery and whose disease had at least stabilised following chemoradiotherapy.

Merck said it would discuss the data with experts and regulatory authorities over the coming months.

Helvea analyst Odile Rundquist, who cut her price target on Merck by 2 euros to 97 euros a share, said the setback for Stimuvax was another blow for Merck's pharmaceutical division following recent disappointments with cancer drug Erbitux and the earlier failure of cladribine in multiple sclerosis.

Merck shares fell 3.3 percent to 98.22 euros by 1145 GMT, while Germany's blue-chip DAX index was up 0.2 percent. The market impact was limited by the fact that many Merck analysts had not included Stimuvax sales forecasts in their financial models, given the risky nature of the project.

The news is a much bigger setback for the German company's small U.S. partner Oncothyreon, whose shares fell 70 percent in premarket trading on Nasdaq.

Stimuvax is one of a number so-called therapeutic cancer vaccines being developed by drug companies to fight tumours by stimulating the body's immune system.

The first such vaccine was approved two years ago but Provenge for prostate cancer, made by Dendreon, has met with limited success, due to management missteps and doctors' reluctance to adopt the difficult-to-administer therapy.

A number of other cancer vaccines are in development that analysts believe may be more successful, including a product from GlaxoSmithKline against melanoma and lung cancer which is set to report clinical trial results next year.

Some investors had already been wary about prospects for Stimuvax after Merck said in March the trial would be continued and final data would be presented later than expected, raising doubts over its success.

'Given the history of the drug's development with postponements, discontinuations and break-ups we are not surprised about today's outcome,' DZ Bank analyst Peter Spengler said.

(Editing by Erica Billingham) Keywords: MERCK STIMUVAX/

( 20 7542 5082)(Reuters Messaging:

Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]

UPDATE 1-GSK's 3-in-1 inhalable drug shows promise in asthma study

(Adds background on market opportunity)May 2 (Reuters) - British drugmaker GlaxoSmithKline Plc said on Thursday that its three-in-one drug Trelegy met
[2 May '19 18:41]

UPDATE 4-GSK sees shingles vaccine sales rising, as free cash flow concerns weigh

(Adds details on respiratory drugs performance)* Vaccines unit sales surge 20 percent, led by Shingrix* Shingrix sales to be "significantly" more than
[1 May '19 12:29]

UPDATE 2-Oil firms, exporters drag FTSE 100, while Sainsbury's, LSE outshine

* FTSE 100 down 0.4 pct* FTSE 250 down 0.1 pct* Oil majors, international firms weigh* Sainsbury's jumps on profit beat* Lloyds gains on hopes of more
[1 May '19 09:39]

UPDATE 2-Oil heavyweights, exporters guide FTSE 100 close to 7-month high

* FTSE 100 up 0.9 pct* FTSE 250 up 0.3 pct* Oil majors take main index higher* Oil price surge hits airlines* Softer sterling boosts exporter stocks*
[23 Apr '19 09:48]

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.